PE20071067A1 - Composiciones de rapamicina y cci-779 y metodo para su preparacion - Google Patents

Composiciones de rapamicina y cci-779 y metodo para su preparacion

Info

Publication number
PE20071067A1
PE20071067A1 PE2006001642A PE2006001642A PE20071067A1 PE 20071067 A1 PE20071067 A1 PE 20071067A1 PE 2006001642 A PE2006001642 A PE 2006001642A PE 2006001642 A PE2006001642 A PE 2006001642A PE 20071067 A1 PE20071067 A1 PE 20071067A1
Authority
PE
Peru
Prior art keywords
rapicciona
rapamycin
preparation
tocopherol
cci
Prior art date
Application number
PE2006001642A
Other languages
English (en)
Inventor
Joseph Thomas Rubino
Gandhi Pooja
Lynn Phelan
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38050882&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20071067(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE20071067A1 publication Critical patent/PE20071067A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

REFERIDA A UNA COMPOSICION FARMACEUTICA DE RAPAMICINA QUE COMPRENDE: a) RAPAMICINA CON MENOS DEL 1,5% DE IMPUREZAS OXIDATIVAS E HIDROLITICAS, b) ANTIOXIDANTES Y OPCIONALMENTE EXCIPIENTES FARMACEUTICAMENTE ACEPTABLES, DONDE LA RAPAMICINA SE SELECCIONA DE RAPAMICINA Y 42-ESTER DE RAPAMICINA O CCI-779. EL ANTIOXIDANTE SE SELECCIONA DE TOCOFEROL, VITAMINA C, 2,6-DI-TERC-BUTIL-4-METILFENOL, PREFERENTEMENTE, ALFA-TOCOFEROL. LA COMPOSICION PUEDE CONTENER ACIDO CITRICO ANHIDRO, ALCOHOL DESHIDRATADO Y PROPILENGLICOL. TAMBIEN ESTA REFERIDA A UN METODO DE PREPARACION
PE2006001642A 2005-12-20 2006-12-19 Composiciones de rapamicina y cci-779 y metodo para su preparacion PE20071067A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75218905P 2005-12-20 2005-12-20

Publications (1)

Publication Number Publication Date
PE20071067A1 true PE20071067A1 (es) 2007-11-26

Family

ID=38050882

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006001642A PE20071067A1 (es) 2005-12-20 2006-12-19 Composiciones de rapamicina y cci-779 y metodo para su preparacion

Country Status (17)

Country Link
US (1) US20070142422A1 (es)
EP (1) EP1962819A1 (es)
JP (1) JP2009520818A (es)
KR (1) KR20080077989A (es)
CN (1) CN101340901A (es)
AR (1) AR058561A1 (es)
AU (1) AU2006331874A1 (es)
BR (1) BRPI0620213A2 (es)
CA (1) CA2632239A1 (es)
CR (1) CR10009A (es)
EC (1) ECSP088571A (es)
IL (1) IL191635A0 (es)
NO (1) NO20082446L (es)
PE (1) PE20071067A1 (es)
RU (1) RU2008121713A (es)
TW (1) TW200731967A (es)
WO (1) WO2007075621A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2493878C (en) * 2002-07-30 2013-07-23 Wyeth Parenteral formulations containing a rapamycin hydroxyester
US7563489B2 (en) * 2005-11-30 2009-07-21 Xerox Corporation Radiation curable phase change inks containing curable epoxy-polyamide composite gellants
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
WO2011151704A2 (en) * 2010-06-02 2011-12-08 Fresenius Kabi Oncology Ltd. Stable pharmaceutical compositions of rapamycin esters
US20120237550A1 (en) * 2011-03-16 2012-09-20 Siemens Healthcare Diagnostics Inc. Maintaining Antibody-Binding Activity Of Immunosuppressant Drug Conjugates
EP3054948B1 (en) 2013-10-08 2020-08-12 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
RU2016136348A (ru) * 2014-02-11 2018-03-16 Лэм Терапьютикс, Инк. Рапамицин для лечения лимфангиолейомиоматоза
US10307371B2 (en) 2014-02-11 2019-06-04 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
EP3125875B1 (en) 2014-04-04 2023-06-07 AI Therapeutics, Inc. An inhalable rapamycin formulation for treating age-related conditions
AU2015330905B2 (en) 2014-10-07 2021-02-25 AI Therapeutics, Inc. An inhalable rapamycin formulation for the treatment of pulmonary hypertension
MA40910A (fr) 2014-11-07 2017-09-12 Civitas Therapeutics Inc Poudres de rapamycine pour administration pulmonaire
US20190022073A1 (en) * 2015-09-03 2019-01-24 Nippon Kayaku Kabushiki Kaisha Pharmaceutical composition comprising rapamycin or derivative thereof
WO2017129772A1 (en) 2016-01-29 2017-08-03 Xellia Phamaceuticals Aps Stable pharmaceutical compositions of temsirolimus
CN105687132B (zh) * 2016-03-17 2020-06-12 鲁南贝特制药有限公司 一种坦西莫司注射用浓溶液及其制备方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US546304A (en) * 1895-09-17 Shutter-hook
US4316885A (en) * 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
US4650803A (en) * 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
GB8803836D0 (en) * 1988-02-18 1988-03-16 Glaxo Group Ltd Compositions
US5023236A (en) * 1988-04-07 1991-06-11 Corvas, Inc. Factor VII/VIIA active site inhibitors
GB2242080B (en) * 1990-03-09 1994-12-21 Krone Ag Electrical connectors
US5023264A (en) * 1990-07-16 1991-06-11 American Home Products Corporation Rapamycin oximes
GB9103430D0 (en) * 1991-02-19 1991-04-03 Smithkline Beecham Plc Novel compound
US5120842A (en) * 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5100883A (en) * 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5118678A (en) * 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
US5118677A (en) * 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5480988A (en) * 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5489680A (en) * 1992-10-13 1996-02-06 American Home Products Corporation Carbamates of rapamycin
US5480989A (en) * 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5504091A (en) * 1993-04-23 1996-04-02 American Home Products Corporation Biotin esters of rapamycin
US5463048A (en) * 1994-06-14 1995-10-31 American Home Products Corporation Rapamycin amidino carbamates
US5491231A (en) * 1994-11-28 1996-02-13 American Home Products Corporation Hindered N-oxide esters of rapamycin
US5563145A (en) * 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines
US5780462A (en) * 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
GB9826882D0 (en) * 1998-12-07 1999-01-27 Novartis Ag Organic compounds
US6277983B1 (en) * 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
ES2283344T3 (es) * 1999-10-29 2007-11-01 Kosan Biosciences, Inc. Analogos de la rapamicina.
US6399626B1 (en) * 2000-10-02 2002-06-04 Wyeth Hydroxyesters of 7-desmethylrapamycin
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
JP2005503395A (ja) * 2001-08-22 2005-02-03 ワイス ラパマイシンジアルデヒド
ATE305932T1 (de) * 2001-08-22 2005-10-15 Wyeth Corp Rapanycin29-enole
CA2493878C (en) * 2002-07-30 2013-07-23 Wyeth Parenteral formulations containing a rapamycin hydroxyester
EP1646635A1 (en) * 2003-07-16 2006-04-19 Wyeth Cci-779 isomer c
WO2005016935A2 (en) * 2003-08-07 2005-02-24 Wyeth Regioselective synthesis of cci-779
AU2005233612A1 (en) * 2004-04-14 2005-10-27 Wyeth Proline CCI-779 (proline-rapamycin 42-ester with 2,2-bis (hydroxymethyl) propionic acid) and two-step enzymatic synthesis of proline CCI-779 and CCI-779 using microbial lipase
TW200804399A (en) * 2005-12-07 2008-01-16 Wyeth Corp Scalable process for the preparation of a rapamycin 42-ester from a rapamycin 42-ester boronate

Also Published As

Publication number Publication date
BRPI0620213A2 (pt) 2011-11-01
AR058561A1 (es) 2008-02-13
NO20082446L (no) 2008-08-26
EP1962819A1 (en) 2008-09-03
CR10009A (es) 2008-09-23
US20070142422A1 (en) 2007-06-21
CA2632239A1 (en) 2007-07-05
KR20080077989A (ko) 2008-08-26
IL191635A0 (en) 2009-02-11
CN101340901A (zh) 2009-01-07
WO2007075621A1 (en) 2007-07-05
TW200731967A (en) 2007-09-01
JP2009520818A (ja) 2009-05-28
ECSP088571A (es) 2008-07-30
RU2008121713A (ru) 2010-01-27
AU2006331874A1 (en) 2007-07-05

Similar Documents

Publication Publication Date Title
PE20071067A1 (es) Composiciones de rapamicina y cci-779 y metodo para su preparacion
NO20060977L (no) Mitokinon-derivater anvendt som mitokondrielle malsokende antioksidanter
NZ763449A (en) Stable cannabinoid formulations
AR078159A1 (es) Composicion que contiene palmitoil-etanolamida ultra-micronizada .metodo. compuesto.forma polimorfica.
FI3641819T3 (fi) Kannabidiolin käyttö tuberoosisklerooosikompleksin hoitoon
WO2008063910A3 (en) Method of preparing solid dosage forms of multi-phasic pharmaceutical compositions
ECSP066972A (es) Profármacos mutuos de glucosamina y glucosamina/anti-inflamatorio, composiciones, y métodos
BRPI0518776A2 (pt) composiÇço e mÉtodo para o cuidado oral, e, mÉtodos para inibir a inflamaÇço em um tecido oral de um paciente, e para promover a saéde oral em um paciente
AR082030A1 (es) Composiciones farmaceuticas topicas que comprenden flurbiprofeno, uso y metodo de tratamiento
AR094941A1 (es) Una composición que comprende un compuesto lipídico, un triglicérido y un tensioactivo, y métodos para usarla
AR061047A1 (es) Comprimido bicapa para la prevencion de los accidentes cardiovasculares, su uso, y metodo para la prevencion de accidentes cardiovasculares
WO2011056532A3 (en) Bazedoxifene formulations with antioxidants
WO2003086329A8 (en) Skincare compositions comprising anti-oxidant agents
WO2012049222A3 (en) Novel omega-3 and omega-6 fatty acid compositions and uses thereof
NZ607997A (en) Fungicidal bactericidal and/or antioxidant treatment of foodstuffs via application of formulations comprising an essential oil and a dialkylene glycol
ECSP045277A (es) Composición oftálmica que comprende ascomicina
DE50001610D1 (de) Antioxidative hautpflegemittel
AR044209A1 (es) Composiciones farmaceuticas que comprenden epinastina para el tratamiento de enfermedades de la piel
EP4142715A4 (en) NEW PHARMACEUTICAL FORMULATION FOR C-MET INHIBITOR
Munari et al. Inhibitory effects of Baccharis dracunculifolia on 1, 2-dimethylhidrazine-induced genotoxicity and preneoplastic lesions in rat colon
AR068346A1 (es) Metodos para lograr bienestar sexual aumentado usando composiciones anhidras
EP4023647A4 (en) IMIDAZOPYRIDINL DERIVATIVES AND PHARMACEUTICAL COMPOSITION WITH THEM AS AN ACTIVE SUBSTANCE
AR067320A1 (es) Composicion farmaceutica que comprende la combinacion de un agente antimicrobiano y un agente antioxidante para el tratamiento de infecciones urinarias
EP2659899A3 (en) Lipophilic carrier composition for solubilizing lipophilic bioactive botanical extracts, methods of solubilizing lipophilic bioactive botanical extracts, and methods of using solubilized lipophilic bioactive botanical extracts
WO2011128914A3 (en) Extended release pharmaceutical compositions of pramipexole

Legal Events

Date Code Title Description
FX Voluntary withdrawal